Related Experiment Videos
Transplantation 1994: the year in review
1Department of Surgery, University of Texas Medical School-Houston, USA.
Clinical Transplants
|January 1, 1994
Summary
Organ transplantation has advanced significantly, with a focus shifting to immunosuppressive therapy. New agents aim to improve transplant success by reducing rejection and side effects, moving towards the goal of immunologic tolerance.
Area of Science:
- Medical Science
- Immunology
- Surgical Innovation
Background:
- Organ transplantation has evolved from experimental to established therapy within a generation.
- Technical surgical advances have shifted research focus to immunosuppressive therapy.
- Tacrolimus is approved for liver transplantation, with ongoing trials for broader use.
Purpose of the Study:
- To review progress in transplantation, focusing on immunosuppressive therapy and future directions.
- To evaluate the impact of new immunosuppressive agents on transplant outcomes.
- To explore strategies for achieving immunologic tolerance in transplantation.
Main Methods:
- Review of clinical practice advancements in 1994.
- Analysis of ongoing clinical trials for immunosuppressive agents like tacrolimus, mycophenolate mofetil, Neoral, and sirolimus.
- Examination of multicenter studies and their implications for future trial design.
Main Results:
- New immunosuppressive agents are expected to broaden treatment options and improve transplant results.
- Multicenter studies highlight effective collaboration and inform future clinical trial design.
- Reduced iatrogenic side effects are recognized as crucial for improved transplant outcomes, alongside rejection mitigation.
Conclusions:
- Immunosuppressive management must balance rejection prevention with minimizing patient morbidity and enhancing quality of life.
- Achieving transplant tolerance is an ongoing challenge, with chimerism's role debated.
- Preclinical findings suggest refined donor antigens or cell infusions may be key to tolerance induction.